AMLX: ENDO 2026 Recap; Expert and Mgmt Check-Ins Highlight Growing PBH and High Conviction in Avexitide Ahead of LUCIDITY's Q3 Readout

Research evidence excerpt

AMLX: ENDO 2026 Recap; Expert and Mgmt Check-Ins Highlight Growing PBH and High Conviction in Avexitide Ahead of LUCIDITY's Q3 Readout

e-trial insights from people with PBH that directly informed

LUCIDITY's study design and endpoint strategy. Hypoglycemia reduction was identified

as important to patients, including functional and cognitive impairment. Patients living Market Data with PBH want increased confidence in daily activities and a treatment that addresses 52-Week Range $4.80 - $18.61 their recurrent, unpredictable highs and lows. PBH burden was described in the poster

Shares Out (M) 111.2 as multidimensional, extending beyond glucose thresholds to functional disruption, safety

Market Cap (M) $1,689 concerns, and cumulative daily impact. Hypoglycemia endpoints in LUCIDITY were selected

ADV (3 mo; 000) 1,150 to reflect clinically meaningful impact, integrating glucose levels, hypoglycemia symptoms,

AMLX and participant-informed outcomes.

14.00 Volume (Millions) Price (USD) 20

12.00 18 AMLX's "Characterizing the Burden of Post-Bariatric Hypoglycemia in the United

10.00 16 14 States" Presented by Dr. Colleen Craig Highlighted a Significant Estimated Burden of

8.00

12 PBH in the US on Healthcare Resource Utilization, Economic Impact, and Quality of

6.00

10 Life. Dr. Craig and her colleagues developed the first economic/burden model quantifying

4.00 8

2.00 6 QoL and economic burden of level 2/3 hypoglycemia in PBH. In our discussions with Dr.

0.00 Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun 4 Craig, she noted that the composite of Level 2 and Level 3 events were used together in

Price Volume Created by BlueMatrix this analysis as the levels often go hand-in-hand — patients that experience Level 2 events

often experience Level 3 events as well.